MARKET

PASG

PASG

Passage Bio, Inc.
NASDAQ
3.610
-0.525
-12.70%
Closed 16:10 11/19 EST
OPEN
4.040
PREV CLOSE
4.135
HIGH
4.040
LOW
3.510
VOLUME
3.71K
TURNOVER
0
52 WEEK HIGH
20.00
52 WEEK LOW
3.290
MARKET CAP
11.62M
P/E (TTM)
-0.3490
1D
5D
1M
3M
1Y
5Y
1D
Passage Bio, Inc. Reports Financial Information for Proposed Merger with Remix Therapeutics, Inc.
NASDAQ · 8h ago
Passage Bio Stockholders Approve Remix Merger Proposals
TipRanks · 13h ago
Passage Bio Announces Updated Phase 1 Trial Results
TipRanks · 20h ago
Passage Bio, Inc. Reports Remix Therapeutics' Phase 1 Data for REM-422 with 57% Response Rate
NASDAQ · 23h ago
Passage Bio, Inc. Receives Nasdaq Notice of Failure to Satisfy $2,500,000 Stockholders' Equity Requirement
NASDAQ · 1d ago
Passage Bio Receives Nasdaq Notice Over Equity Requirement
TipRanks · 1d ago
Weekly Report: what happened at PASG last week (1109-1113)?
Weekly Report · 4d ago
Weekly Report: what happened at PASG last week (1102-1106)?
Weekly Report · 11/09 09:42
More
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Webull offers Passage Bio Inc stock information, including NASDAQ: PASG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PASG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PASG stock methods without spending real money on the virtual paper trading platform.